HC Wainwright Issues Optimistic Forecast for DTIL Earnings

Precision BioSciences, Inc. (NASDAQ:DTIL) – Stock analysts at HC Wainwright increased their FY2027 earnings estimates for Precision BioSciences in a research note issued to investors on Tuesday, November 5th. HC Wainwright analyst P. Trucchio now anticipates that the company will post earnings of $0.20 per share for the year, up from their prior estimate of $0.19. HC Wainwright has a “Buy” rating and a $60.00 price target on the stock. The consensus estimate for Precision BioSciences’ current full-year earnings is $0.82 per share. HC Wainwright also issued estimates for Precision BioSciences’ FY2028 earnings at $0.40 EPS.

Precision BioSciences Price Performance

DTIL opened at $8.46 on Wednesday. Precision BioSciences has a 1-year low of $7.97 and a 1-year high of $19.43. The stock has a market cap of $61.17 million, a P/E ratio of 40.69 and a beta of 1.71. The stock’s 50 day simple moving average is $9.34 and its 200 day simple moving average is $10.06.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Precision BioSciences stock. Janus Henderson Group PLC purchased a new position in shares of Precision BioSciences, Inc. (NASDAQ:DTIL) in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 573,052 shares of the company’s stock, valued at approximately $7,739,000. Janus Henderson Group PLC owned approximately 8.29% of Precision BioSciences at the end of the most recent reporting period. 37.99% of the stock is currently owned by hedge funds and other institutional investors.

About Precision BioSciences

Precision BioSciences, Inc, an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA.